关于顺铂对着色性干皮病癌症患者引起严重不良事件的警示。
Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum.
作者信息
Sumiyoshi Makoto, Soda Hiroshi, Sadanaga Noriaki, Taniguchi Hirokazu, Ikeda Takaya, Maruta Hiroshi, Dotsu Yosuke, Ogawara Daiki, Fukuda Yuichi, Mukae Hiroshi
机构信息
Department of Respiratory Medicine, Sasebo City General Hospital, Japan.
Department of Surgery, Saiseikai Fukuoka General Hospital, Japan.
出版信息
Intern Med. 2017;56(8):979-982. doi: 10.2169/internalmedicine.56.7866. Epub 2017 Apr 15.
Abstract
Xeroderma pigmentosum (XP) is a genetic disease in which DNA repair mechanisms are impaired. Cisplatin (CDDP) exerts cytotoxic effects by forming mainly intrastrand DNA cross-links, and sensitivity to CDDP depends on the DNA repair system. Several in vitro studies have suggested that treatment with CDDP may cause enhanced adverse events as well as anti-tumor activity in cancer patients with XP. This article is the first to describe two cancer patients with XP showing severe adverse events following CDDP-based chemotherapy. Physicians should pay attention when administering CDDP in cancer patients with XP.
摘要
着色性干皮病（XP）是一种DNA修复机制受损的遗传性疾病。顺铂（CDDP）主要通过形成链内DNA交联发挥细胞毒性作用，对CDDP的敏感性取决于DNA修复系统。多项体外研究表明，对于患有XP的癌症患者，使用CDDP治疗可能会导致不良事件增加以及抗肿瘤增强以及抗肿瘤活性。本文首次描述了两名患有XP的癌症患者在接受基于CDDP的化疗后出现严重不良事件。医生在给患有XP的癌症患者使用CDDP时应予以注意。
相似文献
1
Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum.
Intern Med. 2017;56(8):979-982. doi: 10.2169/internalmedicine.56.7866. Epub 2017 Apr 15.
2
Severe cisplatin-induced renal toxicity in a patient with xeroderma pigmentosum.
J Oncol Pharm Pract. 2022 Mar;28(2):466-470. doi: 10.1177/10781552211038246. Epub 2021 Oct 14.
3
Use of host cell reactivation of cisplatin-treated adenovirus 5 in human cell lines to detect repair of drug-treated DNA.
Chem Biol Interact. 1989;71(4):353-65. doi: 10.1016/0009-2797(89)90110-5.
4
Unusual intraoral cancer with unexpected outcome in a patient with xeroderma pigmentosum: An alert for antineoplastic treatment.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2020 Jan;129(1):e1-e11. doi: 10.1016/j.oooo.2019.09.017. Epub 2019 Oct 12.
5
DNA cross-linked by cisplatin: a new probe for the DNA repair defect in xeroderma pigmentosum.
Mol Biol Med. 1987 Oct;4(5):277-90.
6
Restoration of proliferating cell nuclear antigen (PCNA) complex formation in xeroderma pigmentosum group A cells following cis-diamminedichloroplatinum (II)-treatment by cell fusion with normal cells.
J Cell Physiol. 1992 Sep;152(3):639-45. doi: 10.1002/jcp.1041520324.
7
A new anticancer platinum compound, (-)-(R)-2-aminomethyl-pyrrolidine(1,1-cyclobutanedicarboxylato) platinum(II): DNA interstrand crosslinking, repair and lethal effects in normal human, Fanconi's anaemia and xeroderma pigmentosum cells.
Br J Cancer. 1993 Jun;67(6):1285-92. doi: 10.1038/bjc.1993.239.
8
Mutational spectrum of Xeroderma pigmentosum group A in Egyptian patients.
Gene. 2014 Jan 1;533(1):52-6. doi: 10.1016/j.gene.2013.09.125. Epub 2013 Oct 14.
9
Clinical, genetic and DNA repair studies on a consecutive series of patients with xeroderma pigmentosum.
Q J Med. 1979 Apr;48(190):179-210.
10
Xeroderma pigmentosum variant with multisystem involvement.
Arch Dermatol. 1992 Sep;128(9):1233-7.
引用本文的文献
1
Four germline POLH variants, including two found in skin tumors, impair DNA polymerase η function and cellular tolerance to UV radiation and cisplatin.
Chem Biol Interact. 2025 Aug 1;416:111551. doi: 10.1016/j.cbi.2025.111551. Epub 2025 May 5.
2
Cutaneous Squamous Cell Carcinoma and Multiple Basal Cell Carcinomas in Xeroderma Pigmentosum-Variant Type Treated with Imiquimod 5% Cream and Radiotherapy: A Case Report.
Acta Med Philipp. 2024 Sep 30;58(17):100-105. doi: 10.47895/amp.v58i17.9208. eCollection 2024.
3
Diffuse large B-cell lymphoma with cutaneous involvement in a patient with xeroderma pigmentosum type C.
JAAD Case Rep. 2024 May 7;49:28-31. doi: 10.1016/j.jdcr.2024.04.039. eCollection 2024 Jul.
4
Early-onset gynecological tumors in DNA repair-deficient xeroderma pigmentosum group C patients: a case series.
Commun Med (Lond). 2023 Aug 11;3(1):109. doi: 10.1038/s43856-023-00341-6.
5
The French Cohort of DNA Repair-Deficient Xeroderma Pigmentosum Patients: Risk of Hematological Malignancies.
Cancers (Basel). 2023 May 10;15(10):2706. doi: 10.3390/cancers15102706.
6
Identification of Three Human POLH Germline Variants Defective in Complementing the UV- and Cisplatin-Sensitivity of POLH-Deficient Cells.
Int J Mol Sci. 2023 Mar 8;24(6):5198. doi: 10.3390/ijms24065198.
7
Pathological consequences of DNA damage in the kidney.
Nat Rev Nephrol. 2023 Apr;19(4):229-243. doi: 10.1038/s41581-022-00671-z. Epub 2023 Jan 26.
8
Lung adenocarcinoma concomitant with xeroderma pigmentosum: a case report.
J Med Case Rep. 2021 Mar 30;15(1):160. doi: 10.1186/s13256-021-02754-0.
9
Response to Pembrolizumab in a Patient With Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma.
JCO Precis Oncol. 2019 Sep 20;3. doi: 10.1200/PO.19.00028. eCollection 2019.
10
A case of severe hepatotoxicity induced by cisplatin and 5-fluorouracil.
Int Cancer Conf J. 2019 Nov 19;9(1):24-27. doi: 10.1007/s13691-019-00394-2. eCollection 2020 Jan.
本文引用的文献
1
Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies.
Toxics. 2015 Jul 15;3(3):268-293. doi: 10.3390/toxics3030268.
2
Xeroderma pigmentosum clinical practice guidelines.
J Dermatol. 2017 Oct;44(10):1087-1096. doi: 10.1111/1346-8138.13907. Epub 2017 Aug 3.
3
Role of the XPA protein in the NER pathway: A perspective on the function of structural disorder in macromolecular assembly.
Comput Struct Biotechnol J. 2015 Dec 8;14:78-85. doi: 10.1016/j.csbj.2015.11.007. eCollection 2016.
4
Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells.
Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):4411-6. doi: 10.1073/pnas.1421365112. Epub 2015 Mar 23.
5
Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer.
Genomics Proteomics Bioinformatics. 2014 Oct;12(5):198-209. doi: 10.1016/j.gpb.2014.10.003. Epub 2014 Oct 28.
6
Structural and mechanistic studies of polymerase η bypass of phenanthriplatin DNA damage.
Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9133-8. doi: 10.1073/pnas.1405739111. Epub 2014 Jun 9.
7
DNA repair diseases: What do they tell us about cancer and aging?
Genet Mol Biol. 2014 Mar;37(1 Suppl):220-33. doi: 10.1590/s1415-47572014000200008.
8
Bypass of DNA lesions generated during anticancer treatment with cisplatin by DNA polymerase eta.
Science. 2007 Nov 9;318(5852):967-70. doi: 10.1126/science.1148242.
9
A role for polymerase eta in the cellular tolerance to cisplatin-induced damage.
Cancer Res. 2005 Nov 1;65(21):9799-806. doi: 10.1158/0008-5472.CAN-05-1095.
10
Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells.
Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5874-9.
Zotero 插件